Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

38.17 +0.95 (+2.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,825,939
Open 37.78
Bid (Size) 37.50 (1)
Ask (Size) 38.13 (2)
Prev. Close 37.22
Today's Range 37.60 - 38.25
52wk Range 36.91 - 58.10
Shares Outstanding 1,250,690,553
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
NASDAQ:SNY Investor Alert: Investigation over Potential Wrongdoing at Sanofi
San Diego, CA -- (SBWIRE) -- 09/20/2022 -- An investigation on behalf of investors in shares of Sanofi (NASDAQ:SNY) was announced over potential breaches of fiduciary duties by certain directors at... 
Via SBWire

Performance

YTD
-24.70%
-24.70%
1 Month
-6.22%
-6.22%
3 Month
-27.53%
-27.53%
6 Month
-26.03%
-26.03%
1 Year
-20.31%
-20.31%

More News

Read More
Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer
Via Benzinga
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger
Via Benzinga
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
Via Benzinga
ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients
Via Benzinga
Sanofi's Rare Disease Drug Xenpozyme Scores FDA Approval
Via Benzinga
Sanofi's Hemophilia Candidate Goes Under Priority FDA Review
Via Benzinga
TG Therapeutics Touts Encouraging Data From Multiple Sclerosis Candidate
Via Benzinga
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease
Via Benzinga
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
Via Benzinga
Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids
Via Benzinga
Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash...
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Via Benzinga
Upstart Digital Health Company, DarioHealth, Announces Significant Contract with National Health Plan Provider, Giving Millions Access to Mental Health Resources
Via Benzinga
MarketBeat: Week in Review 8/15 - 8/19
Via MarketBeat
Topics Economy Workforce
Exposures Economy Interest Rates Layoff
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Is Sanofi A Buy, Despite Recent Stumbles?
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Via News Direct
Exposures Product Safety
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Via TheNewswire.com
Exposures Product Safety
Sanofi's Breast Cancer Drug Fallout 'Creates Buying Opportunity' For This Stock
Via Benzinga
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.